Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS: Part II.

H A Kessler1, J A Bick, J C Pottage

  • 1Section of Infectious Disease, Rush Medical College, Chicago, Illinois.

Disease-A-Month : DM
|October 11, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nevirapine pharmacokinetics in HIV-infected persons receiving rifapentine and isoniazid for TB prevention.

The Journal of antimicrobial chemotherapy·2020
Same author

Cerebral organoids reveal early cortical maldevelopment in schizophrenia-computational anatomy and genomics, role of FGFR1.

Translational psychiatry·2018
Same author

Digitizing Medicines for Remote Capture of Oral Medication Adherence Using Co-encapsulation.

Clinical pharmacology and therapeutics·2017
Same author

Common developmental genome deprogramming in schizophrenia - Role of Integrative Nuclear FGFR1 Signaling (INFS).

Schizophrenia research·2017
Same author

Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2016
Same author

"Nuclear FGF receptor-1 and CREB binding protein: an integrative signaling module".

Journal of cellular physiology·2014
Same journal

Disturbances due to cold.

Disease-a-month : DM·2026
Same journal

GLP-1 agonist and neuroprotection in Stroke and Parkinson's disease: A systematic review.

Disease-a-month : DM·2026
Same journal

GLP-1 receptor agonists for weight management and potential thromboembolic risk reduction in high risk population with cancer, diabetes, cardiovascular disease: A systematic review.

Disease-a-month : DM·2026
Same journal

Periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same journal

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same journal

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
See all related articles

Zidovudine is the primary drug for treating human immunodeficiency virus (HIV) infection, improving quality of life and delaying AIDS progression. Other drugs like didanosine and zalcitabine offer alternatives but have associated toxicities.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • Human immunodeficiency virus (HIV) infection significantly impacts immune function, leading to opportunistic infections and malignancies.
  • Current therapies for HIV infection primarily target the reverse transcriptase enzyme.

Purpose of the Study:

  • To review the efficacy and toxicities of approved and investigational drugs for HIV therapy.
  • To discuss the management of opportunistic infections in patients with advanced HIV disease.

Main Methods:

  • Review of current literature on HIV therapeutics.
  • Analysis of clinical efficacy and adverse event profiles of zidovudine, didanosine, and zalcitabine.

Main Results:

  • Zidovudine demonstrates clinical efficacy in prolonging life and improving quality of life for HIV patients, including asymptomatic individuals.

Related Experiment Videos

  • Didanosine and zalcitabine are associated with peripheral neuropathy and pancreatitis, while zidovudine's major toxicity is bone marrow suppression.

    • Conclusions:

    • Early intervention with zidovudine can delay the progression to acquired immune deficiency syndrome (AIDS).
    • Management of HIV infection involves a combination of antiretroviral therapy and prophylaxis against opportunistic infections.